Gardasil Syndrome

https://www.gardasilsyndrome.com/

Health and Human Services (HHS) holds patents (Licensee) for the Virus Like Particles (VLPs) used in vaccines such as the Gardasil and Gardasil9 HPV vaccines. As such, they may be considered a party to the vaccine manufacturing process. As such, it appears they may have both a Fiduciary and Statutory duty to inform vaccine recipients and everyone in the chain of delivery of said vaccine(s) that:

1). The DNA of the HPV16-L1 VLP is virtually identical (95-98% DNA Match) to the Rhesus Monkey Papilloma Virus RMPV L1 Protein of the virus contained in the injectable Salk Polio Vaccine (IPV) of the mid 1950s to the early 1960s. Injecting the Gardasil/Gardasil9 HPV vaccine into the Germline (offspring of a parent or grandparent who received the Salk Polio vaccine) and carries the RMPV, may cause the immune system of the recipient to develop antibodies that may attack human cells containing the dormant (latent) RMPV. This may incorrectly be diagnosed as an "Autoimmune Disease." In reality, the Gardasil HPV vaccine may directly CAUSE the immune system to attack its human host.

................................................................................................................

Gardasil Syndrome appears to be a very complex multiphasic immune suppression disorder centered around a vaccine induced form of Hemophagocytic Lymphohistiocytosis in a host with one or more markers consistent with an MUNC13-4 deficiency, who also has an asymptomatic moderate to high pathogen load in homeostasis. The severity of symptoms may vary greatly due to genetic mutations and polymorphisms, plus pathogen load and body burden.

................................................................................................................

The following conditions were found to be most common in this Retrospective Study which has now grown to several hundred children and adults over a seven year span:

1) More than 90% report that they rarely were sick BEFORE they received the Gardasil or Cervarix HPV vaccine.
2) A HAPLOTYPE which allows a high(er) pathogen load in the host (ie: HLA-DRB1/DR/DQ/B27 (~MUNC13-4 deficiency)
3) Presence of Ehlers-Danlos Type 3 (Hypermobility) or 4 (vascular). Both are associated with an MUNC13-4 deficiency.
4) Ancient ancestors from BERINGIA, such as Native American, First Nation, Mayan, etc., also associated with MUNC13-4 deficiency)
5) Very high pathogen loads were discovered POST vaccination, consistent with a reactivation of latent pathogens following a sepsis-like condition, initiated by the AAHS adjuvant in the Gardasil HPV vaccine.